Dr. Chue is a Clinical Professor in the Department of Psychiatry at the University of Alberta, Senior Medical Advisor Strategic Initiatives, Edmonton Zone, Addictions and Mental Health,Alberta Health Services, Mental Health Lead, Continuing Care, Edmonton Zone, and Consulting Psychiatrist with Telemental Health Services for the Province of Alberta and the Mental Health Review Panel for the Government of Alberta.
Dr. Chue is a full-time clinician with a focus on community psychiatry and was involved in the development of the first Assertive Community Team (ACT) and mobile Mental Health Crisis Team in Alberta. He supervises the Intensive Community Transitions Team and provides domiciliary consultation for patients in shelters, group homes, police stations and correctional facilities.
Dr. Chue completed his medical degree (MBBCh) and psychiatric specialization (MRCPsych) in the UK before moving to Canada in 1991 where he subsequently obtained Canadian medical (LMCC) and specialist qualifications (FRCPC) as well as American Boards Certification in Psychiatry and Neurology (DABPN) and an MSc in Psychiatry at the University of Alberta. He was elected a Fellow of the Royal College of Psychiatrists (FRCPsych) in the UK in 2004.
Dr Chue’s has a particular interest in clinical psychopharmacology, particularly concerning psychotropic side effects (movement disorder, metabolic syndrome, sexual dysfunction, sudden unexplained death, drug-drug interactions), adherence, patient satisfaction, drug delivery systems, etc. He is the Director of the Clinical Trials and Research Program, Edmonton, and has been involved in more than 50 clinical trials in the areas of schizophrenia, bipolar disorder, depression, anxiety disorders, smoking cessation, and sexual dysfunction. He has also designed and run, as principal investigator, numerous national and international clinical trials as well as conducting rater training and developing patient satisfaction rating and functionality scales.
Dr. Chue is a researcher with the Integrative Health Institute, Centre of Excellence for Real World Clinical Outcomes, Neuroscience and Mental Health Institute and Campus Alberta Neuroscience at the University of Alberta.
Dr Chue is author or co-author of more than 140 articles and abstracts in peer reviewed medical journals, book chapters, and scientific symposia; he has published several Cochrane Reviews and contributed to national guidelines. He is a reviewer for psychiatric journals and Psychiatry Research Awards Program. He teaches students in healthcare disciplines from around the world. He has given more than 600 presentations as a visiting professor and/or invited contributor at major psychiatric congresses and universities as well as media interviews in English and French. He was rated in the 2004 Canadian Universities Cormex Report as the most frequently quoted physician in the Canadian media.
As a medical educator he has facilitated knowledge transfer and continuous professional development and developed accredited (national and international) educational programs, master classes, symposia and conferences, clinical practice tools and audit applications for healthcare professionals for Universities, Canadian Psychiatric Association, Royal College of Physicians and Surgeons of Canada, Alberta Health Services, Institute of Health Economics and industry. He has completed evaluations of clinical competency and clinical practice readiness for the College of Physicians and Surgeons of Alberta as well as supervising IMG/FMGs.
Dr Chue has acted as an expert (psychiatry, psychopharmacology) for the coroner’s office, police, health authorities and hospitals (Canada and US), pharmaceutical, IME and insurance companies, major corporations, law firms, Justice Canada, Canadian Border Services Agency, Canadian Medical Protective Association, and College of Physicians and Surgeons of Alberta. He has chaired the Medical Panel of the Alberta Workers Compensation Board. He has testified as an expert witness in Canada, US, and UK on an individual plaintiff basis and for national class action law suits. He has provided submissions to reimbursement, approval and formulary committees including the Therapeutic Products Directorate and Patent Medicines Price Review Board for the Government of Canada, Ontario Drug Benefit Plan as well as Alberta Blue Cross.